logo-loader
RNS
ProBiotix Health PLC

Probiotix Health PLC - New Commercial Partnership in Sweden

RNS Number : 1884D
Probiotix Health PLC
14 October 2025
 

14 October 2025

 

ProBiotix Health plc

("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")

 

New Commercial Partnership in Sweden

 

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce a commercial partnership with Sweden based RevivaBio.

 

ProBiotix has entered a commercial cooperation with RevivaBio, one of Sweden's fastest growing health companies, to launch a new cholesterol lowering product powered by the ProBiotix patented probiotic strain LPLDL®. The collaboration marks an important step in RevivaBio's strategy, through new product introductions based on scientifically validated ingredients.

 

After an extensive evaluation of innovations in cardiometabolic health, RevivaBio selected LPLDL® for its clinically validated ability to help manage cholesterol levels safely and effectively. RevivaBio's new product will be introduced and launched in Sweden and a number of APAC markets during Q1 2026, in a capsule dietary supplement under RevivaBio's own brand. The product will be distributed through health stores as well as through e-commerce activities. As part of the collaboration, ProBiotix will manufacture the primary finished capsules product and RevivaBio will be responsible for the final packaging of the product.

 

Founded in 2002 and headquartered in Uppsala, RevivaBio has become a recognised player in the Swedish health and nutrition market. The company develops, manufactures, and sells a wide range of science-based dietary supplements focused on gut health, histamine intolerance, inflammation, and immune balance. With its own modern production facility and a dedicated team, RevivaBio is known for its high-quality standards, innovation, and customer focus.

 

RevivaBio's portfolio includes well-known products such as DAOfood®, Daosin®, and Atrantil.

 

The company has built a strong reputation for customer satisfaction and trust, being recommended on Sweden's leading review platform, Reco.se, for seven consecutive years, with an average customer rating of 4.6 out of 5 from more than 700 verified reviews.

 

Cardiovascular disease remains one of the leading health challenges in Sweden and globally. RevivaBio aims to make a meaningful contribution to heart health by offering scientifically proven and natural solutions.

 

Steen Andersen, CEO of ProBiotix, commented: "The collaboration marks another important step in our ambition to further our expansion internationally. We are delighted to be working with RevivaBio to develop a new probiotic product, which we believe will prove a highly successful new offering.

 

"The cooperation further demonstrates the growing global demand for probiotic products that support heart health, and is expected to help further accelerate our sales growth."

 

Thomas Frid, General Manager of RevivaBio, added: "Partnering with ProBiotix Health and introducing LPLDL® is a major milestone for us. We are proud to strengthen our product portfolio with a world-leading probiotic innovation.

 

"Together, we can make a real difference in improving heart health, both here in Sweden and abroad."

 

For further information, please contact:

 

ProBiotix Health plc

https://probiotixhealth-ir.com/

 

investors@probiotixhealth.com

Steen Andersen, Chief Executive Officer

Miles Nolan, Investor Relations

 



Peterhouse Capital Limited

Aquis Corporate Adviser and Broker

 

 

 

Mark Anwyl

Duncan Vasey

 

Tel: 020 7469 0930

 


This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

Notes to Editors:

 

ProBiotix is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.

 

The Company has a singular approach: discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXBIBDGDXBDGUX
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read